Single User License
INR 134840
Site License
INR 269680
Corporate User License
INR 404520

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Acute Pain-Pipeline Review, H1 2015

Acute Pain-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Acute Pain-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Acute Pain-Pipeline Review, H1 2015', provides an overview of the Acute Pain's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Pain and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Acute Pain

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Acute Pain and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Acute Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Acute Pain pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Acute Pain

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Acute Pain pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Acute Pain Overview 9

Therapeutics Development 10

Pipeline Products for Acute Pain-Overview 10

Pipeline Products for Acute Pain-Comparative Analysis 11

Acute Pain-Therapeutics under Development by Companies 12

Acute Pain-Therapeutics under Investigation by Universities/Institutes 16

Acute Pain-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Unknown Stage Products 20

Acute Pain-Products under Development by Companies 21

Acute Pain-Products under Investigation by Universities/Institutes 26

Acute Pain-Companies Involved in Therapeutics Development 27

A. Menarini Industrie Farmaceutiche Riunite Srl 27

AcelRx Pharmaceuticals, Inc. 28

Adynxx, Inc. 29

AnaBios Corporation 30

Anavex Life Sciences Corp. 31

AngioChem Inc. 32

Antibe Therapeutics, Inc. 33

Cara Therapeutics, Inc. 34

Charleston Laboratories, Inc. 35

ChironWells GmbH 36

Cytogel Pharma, LLC 37

Glenmark Pharmaceuticals Ltd. 38

Grunenthal GmbH 39

Iroko Pharmaceuticals, LLC 40

KemPharm, Inc. 41

Kineta, Inc. 42

Laboratorios Del Dr. Esteve S.A. 43

Mallinckrodt plc 44

MEDRx Co., Ltd. 45

Merck & Co., Inc. 46

Nanomerics Ltd 47

Nektar Therapeutics 48

Nuvo Research Inc. 49

Orbis Biosciences, Inc. 50

Pacira Pharmaceuticals, Inc. 51

Paladin Labs Inc. 52

Rottapharm SpA 53

Santen Pharmaceutical Co., Ltd. 54

Sigma-Tau S.p.A. 55

Syntrix Biosystems, Inc. 56

Thar Pharmaceuticals, Inc. 57

Trevena, Inc. 58

Yungjin Pharm Ind. Co., Ltd. 59

Acute Pain-Therapeutics Assessment 60

Assessment by Monotherapy Products 60

Assessment by Combination Products 61

Assessment by Target 62

Assessment by Mechanism of Action 65

Assessment by Route of Administration 68

Assessment by Molecule Type 70

Drug Profiles 72

(acetaminophen + tramadol hydrochloride)-Drug Profile 72

(acetaminophen + tramadol hydrochloride) SR-Drug Profile 74

(benzhydrocodone hydrochloride + acetaminophen)-Drug Profile 75

(celecoxib + tramadol hydrochloride)-Drug Profile 76

(dexketoprofen trometamol + tramadol hydrochloride)-Drug Profile 77

(etodolac + lidocaine)-Drug Profile 78

(etoricoxib + tizanidine)-Drug Profile 80

(hydrocodone + acetaminophen) ER-Drug Profile 81

(lidocaine + tetracaine)-Drug Profile 82

AAT-008-Drug Profile 84

AAT-076-Drug Profile 85

ANAVEX-1037-Drug Profile 86

ANAVEX-1066-Drug Profile 87

ANAVEX-1067-Drug Profile 88

ANAVEX-1519-Drug Profile 89

ANG-2002-Drug Profile 90

ARX-01-Drug Profile 91

ARX-04-Drug Profile 94

ATB-352-Drug Profile 95

AYX-1-Drug Profile 96

BBI-11008-Drug Profile 97

celecoxib nanoformulation-Drug Profile 98

CL-108-Drug Profile 99

CLH-10-Drug Profile 100

CLH-5-Drug Profile 101

CMX-020-Drug Profile 102

conolidine-Drug Profile 103

CR-4056-Drug Profile 104

CR-845-Drug Profile 105

Cyt-1010-Drug Profile 107

DepoNSAID ER-Drug Profile 109

E-52862-Drug Profile 110

ET-1-Drug Profile 112

FY-101C-Drug Profile 113

FY-103B-Drug Profile 114

GIBH-1014-Drug Profile 115

grapiprant-Drug Profile 116

GRC-27864-Drug Profile 118

HS-731-Drug Profile 119

ibuprofen-Drug Profile 120

ibuprofen nanoformulation-Drug Profile 121

ketamine hydrochloride-Drug Profile 122

lidocaine-Drug Profile 123

Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain-Drug Profile 124

NKTR-192-Drug Profile 125

NKTR-196-Drug Profile 126

NM-0127-Drug Profile 127

Omnitram-Drug Profile 128

prednisone-Drug Profile 129

Prostatic Acid Phosphatase-Drug Profile 130

RO-656570-Drug Profile 131

SA-14867-Drug Profile 132

Small Molecules to Agonize Kappa Opioid Receptor for CNS Disorder-Drug Profile 133

Small Molecules to Block Nav 1.7 for Pain-Drug Profile 134

Small Molecules to Block Nav 1.8 for Pain-Drug Profile 135

ST-4070-Drug Profile 136

T-109-Drug Profile 137

tapentadol hydrochloride-Drug Profile 138

TRV-130-Drug Profile 139

TRV-734-Drug Profile 141

U-2902-Drug Profile 142

VPX-595-Drug Profile 143

X-0002-Drug Profile 144

ZEP-3-Drug Profile 146

Acute Pain-Recent Pipeline Updates 148

Acute Pain-Dormant Projects 171

Acute Pain-Discontinued Products 177

Acute Pain-Product Development Milestones 179

Featured News & Press Releases 179

Appendix 187

Methodology 187

Coverage 187

Secondary Research 187

Primary Research 187

Expert Panel Validation 187

Contact Us 187

Disclaimer 188

List of Tables

Number of Products under Development for Acute Pain, H1 2015 14

Number of Products under Development for Acute Pain-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 17

Number of Products under Development by Companies, H1 2015 (Contd..1) 18

Number of Products under Development by Companies, H1 2015 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H1 2015 20

Comparative Analysis by Late Stage Development, H1 2015 21

Comparative Analysis by Clinical Stage Development, H1 2015 22

Comparative Analysis by Early Stage Development, H1 2015 23

Comparative Analysis by Unknown Stage Development, H1 2015 24

Products under Development by Companies, H1 2015 25

Products under Development by Companies, H1 2015 (Contd..1) 26

Products under Development by Companies, H1 2015 (Contd..2) 27

Products under Development by Companies, H1 2015 (Contd..3) 28

Products under Development by Companies, H1 2015 (Contd..4) 29

Products under Investigation by Universities/Institutes, H1 2015 30

Acute Pain-Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 31

Acute Pain-Pipeline by AcelRx Pharmaceuticals, Inc., H1 2015 32

Acute Pain-Pipeline by Adynxx, Inc., H1 2015 33

Acute Pain-Pipeline by AnaBios Corporation, H1 2015 34

Acute Pain-Pipeline by Anavex Life Sciences Corp., H1 2015 35

Acute Pain-Pipeline by AngioChem Inc., H1 2015 36

Acute Pain-Pipeline by Antibe Therapeutics, Inc., H1 2015 37

Acute Pain-Pipeline by Cara Therapeutics, Inc., H1 2015 38

Acute Pain-Pipeline by Charleston Laboratories, Inc., H1 2015 39

Acute Pain-Pipeline by ChironWells GmbH, H1 2015 40

Acute Pain-Pipeline by Cytogel Pharma, LLC, H1 2015 41

Acute Pain-Pipeline by Glenmark Pharmaceuticals Ltd., H1 2015 42

Acute Pain-Pipeline by Grunenthal GmbH, H1 2015 43

Acute Pain-Pipeline by Iroko Pharmaceuticals, LLC, H1 2015 44

Acute Pain-Pipeline by KemPharm, Inc., H1 2015 45

Acute Pain-Pipeline by Kineta, Inc., H1 2015 46

Acute Pain-Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2015 47

Acute Pain-Pipeline by Mallinckrodt plc, H1 2015 48

Acute Pain-Pipeline by MEDRx Co., Ltd., H1 2015 49

Acute Pain-Pipeline by Merck & Co., Inc., H1 2015 50

Acute Pain-Pipeline by Nanomerics Ltd, H1 2015 51

Acute Pain-Pipeline by Nektar Therapeutics, H1 2015 52

Acute Pain-Pipeline by Nuvo Research Inc., H1 2015 53

Acute Pain-Pipeline by Orbis Biosciences, Inc., H1 2015 54

Acute Pain-Pipeline by Pacira Pharmaceuticals, Inc., H1 2015 55

Acute Pain-Pipeline by Paladin Labs Inc., H1 2015 56

Acute Pain-Pipeline by Rottapharm SpA, H1 2015 57

Acute Pain-Pipeline by Santen Pharmaceutical Co., Ltd., H1 2015 58

Acute Pain-Pipeline by Sigma-Tau S.p.A., H1 2015 59

Acute Pain-Pipeline by Syntrix Biosystems, Inc., H1 2015 60

Acute Pain-Pipeline by Thar Pharmaceuticals, Inc., H1 2015 61

Acute Pain-Pipeline by Trevena, Inc., H1 2015 62

Acute Pain-Pipeline by Yungjin Pharm Ind. Co., Ltd., H1 2015 63

Assessment by Monotherapy Products, H1 2015 64

Assessment by Combination Products, H1 2015 65

Number of Products by Stage and Target, H1 2015 67

Number of Products by Stage and Mechanism of Action, H1 2015 70

Number of Products by Stage and Route of Administration, H1 2015 73

Number of Products by Stage and Molecule Type, H1 2015 75

Acute Pain Therapeutics-Recent Pipeline Updates, H1 2015 152

Acute Pain-Dormant Projects, H1 2015 175

Acute Pain-Dormant Projects (Contd..1), H1 2015 176

Acute Pain-Dormant Projects (Contd..2), H1 2015 177

Acute Pain-Dormant Projects (Contd..3), H1 2015 178

Acute Pain-Dormant Projects (Contd..4), H1 2015 179

Acute Pain-Dormant Projects (Contd..5), H1 2015 180

Acute Pain-Discontinued Products, H1 2015 181

Acute Pain-Discontinued Products (Contd..1), H1 2015 182

List of Figures

Number of Products under Development for Acute Pain, H1 2015 14

Number of Products under Development for Acute Pain-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 16

Comparative Analysis by Late Stage Development, H1 2015 21

Comparative Analysis by Clinical Stage Development, H1 2015 22

Comparative Analysis by Early Stage Products, H1 2015 23

Assessment by Monotherapy Products, H1 2015 64

Assessment by Combination Products, H1 2015 65

Number of Products by Top 10 Targets, H1 2015 66

Number of Products by Stage and Top 10 Targets, H1 2015 66

Number of Products by Top 10 Mechanism of Actions, H1 2015 69

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 69

Number of Products by Top 10 Routes of Administration, H1 2015 72

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 72

Number of Products by Top 10 Molecule Types, H1 2015 74

Number of Products by Stage and Top 10 Molecule Types, H1 2015 74

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

A. Menarini Industrie Farmaceutiche Riunite Srl

AcelRx Pharmaceuticals, Inc.

Adynxx, Inc.

AnaBios Corporation

Anavex Life Sciences Corp.

AngioChem Inc.

Antibe Therapeutics, Inc.

Cara Therapeutics, Inc.

Charleston Laboratories, Inc.

ChironWells GmbH

Cytogel Pharma, LLC

Glenmark Pharmaceuticals Ltd.

Grunenthal GmbH

Iroko Pharmaceuticals, LLC

KemPharm, Inc.

Kineta, Inc.

Laboratorios Del Dr. Esteve S.A.

Mallinckrodt plc

MEDRx Co., Ltd.

Merck & Co., Inc.

Nanomerics Ltd

Nektar Therapeutics

Nuvo Research Inc.

Orbis Biosciences, Inc.

Pacira Pharmaceuticals, Inc.

Paladin Labs Inc.

Rottapharm SpA

Santen Pharmaceutical Co., Ltd.

Sigma-Tau S.p.A.

Syntrix Biosystems, Inc.

Thar Pharmaceuticals, Inc.

Trevena, Inc.

Yungjin Pharm Ind. Co., Ltd.

Acute Pain Therapeutic Products under Development, Key Players in Acute Pain Therapeutics, Acute Pain Pipeline Overview, Acute Pain Pipeline, Acute Pain Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com